Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HS-20117-2 combination therapy in locally advanced or metastatic solid tumors (Phase I/II)
CTR20263162Phase 2Active
- Sponsor
- Hansoh Pharmaceutical Group
- Start
- Aug 2026
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 2 trial of HS-20117-2 in Nonhematologic neoplasms, solid tumor, head and neck squamous cell carcinoma (HNSCC), sponsored by Hansoh Pharmaceutical Group. Started Aug 2026; status: active.
02
Drugs
HS-20117-2
03
Conditions
Nonhematologic neoplasmssolid tumorhead and neck squamous cell carcinoma (HNSCC)
Beyond the preview
Go deeper on CTR20263162.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20263162.